Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K report on January 29, 2004, primarily to disclose its financial results for the fourth quarter and full year of 2003. This filing serves as a mechanism to provide timely information to investors regarding the company's operational and financial performance. The report incorporates by reference a press release (Exhibit 99.1) detailing these results, along with supplemental financial information (Exhibit 99.2) not contained within the press release. Investors reviewing this filing should focus on the details within the referenced press release and supplemental data to understand BMY's recent financial health, revenue trends, profitability, and any key performance indicators for the period. The filing adheres to Regulation FD, ensuring that material information is broadly disseminated to the public.
Key Highlights
- 1BMY filed an 8-K on January 29, 2004, to report its Q4 and full-year 2003 financial results.
- 2The report incorporates a press release (Exhibit 99.1) containing the financial results.
- 3Supplemental financial information not included in the press release is also provided as Exhibit 99.2.
- 4The filing falls under Items 7, 9, and 12 of the Form 8-K, covering Financial Statements/Exhibits, Regulation FD Disclosure, and Results of Operations/Financial Condition.
- 5This disclosure ensures timely and broad dissemination of material financial information to investors.
- 6Investors are directed to the press release and supplemental information for a detailed understanding of the company's 2003 performance.